RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > News: Prescription Drug Television Advertisement Advisory Review Fees – Not This Year

News: Prescription Drug Television Advertisement Advisory Review Fees – Not This Year

Posted 01 March 2008

As previously reported (see Regulatory Affairs Focus, December 2007), the Food and Drug Administration Amendments Act of 2007 (FDAAA) included a provision requiring the payment of fees for advisory review of prescription drug television advertisements by the Food and Drug Administration (FDA).1 At the end of last year, it appeared that this program was on track. On 25 October 2007, FDA issued a Federal Register notice requesting notifications of expected advisory review submissions for Fiscal 2008.2 On 11 December 2007, FDA announced that, based upon the number of notifications received from industry,3 the advisory review fee for Fiscal 2008 would be $41,390 for each proposed television advertisement voluntarily submitted for advisory review.4

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe